`
`~
`LUCENT!S
`RAN I 81 Z WMA. 8
`Business Use Only
`
`Lucentis PFS (RFB002)
`
`Meeting Date: January 23, 2012
`Meeting Notes Date: January 29, 2012
`
`TRD SubTeam meeting
`
`Team Members : (✓ = Present,•= part-time)
`
`Extended Team Present
`
`•
`
`•
`
`I
`
`I
`I
`
`I
`
`Lucentis CMC Sub Team Meeting, Meeting Date: January 23, 2012
`
`1 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2072.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`-I
`
`I
`
`I
`I
`
`Lucentis CMC Sub Team Meeting, Meeting Date: January 23, 2012
`
`2 of 6
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2072.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`-I
`
`I
`
`-I
`
`I
`
`I
`
`Lucentis CMC Sub Team Meeting, Meeting Date: January 23, 2012
`
`3 of 6
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2072.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`... _
`·(cid:173)I
`
`I
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2072.004
`Regeneron v. Novartis, IPR2021 -00816
`
`4 of 6
`
`
`
`-I
`
`Action Plan:
`
`What
`
`Who --- --
`-
`--
`
`--
`
`Lucentis CMC Sub Team Meeting, Meeting Date: January 23, 2012
`
`5 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMAT ION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2072.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`--
`
`Activity description
`
`Code
`- - -- -~
`
`LF
`
`Lucentis CMC Sub Team Meeting, Meeting Date: January 23, 2012
`
`6 of 6
`
`CONTAINS CONFIDENTIAL BUSI NESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2072.006
`Regeneron v. Novartis, IPR2021-00816
`
`